Cited by 303Epigenetics and DNA MethylationChromatin Remodeling and CancerCancer Cells and Metastasis

The DOI matches its Crossref record; 96 of the 96 references it cites were found in a registry or an index.

Poised epigenetic states and acquired drug resistance in cancer

Brown, Robert, Curry, Edward, Magnani, Luca, Wilhelm-Benartzi, Charlotte S., Borley, Jane·2014·Nature Reviews Cancer

Open this paper in CoChat — free account

Abstract

Epigenetic events, which are somatically inherited through cell division, are potential drivers of acquired drug resistance in cancer. The high rate of epigenetic change in tumours generates diversity in gene expression patterns that can rapidly evolve through drug selection during treatment, leading to the development of acquired resistance. This will potentially confound stratified chemotherapy decisions that are solely based on mutation biomarkers. Poised epigenetic states in tumour cells may drive multistep epigenetic fixation of gene expression during the acquisition of drug resistance, which has implications for clinical strategies to prevent the emergence of drug resistance.

Integrity signals

Registry

Crossref · 10.1038/nrc3819

Cites

96 of 96 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Epigenetic Regulations of GABAergic Neurotransmission: Relevance for Neurological Disorders and Epigenetic Therapy
Shrestha, S., & Offer, S. M. (2016) · Medical Epigenetics · doi:10.1159/000444713 · Cited by 8,951
Cancer Genome Landscapes
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
A bivalent chromatin structure marks key developmental genes in embryonic stem cells
Bernstein, B. E., Mikkelsen, T. S., Xie, X., Kamal, M., Huebert, D. J., Cuff, J., Fry, B., Meissner, A., Wernig, M., Plath, K., et al. (2006) · Cell · doi:10.1016/j.cell.2006.02.041 · Cited by 5,361
Cancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681
A decade of exploring the cancer epigenome—biological and translational implications
Baylin, S. B., & Jones, P. A. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3130 · Cited by 2,871
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.027 · Cited by 2,770
The polycomb group protein EZH2 is involved in progression of prostate cancer
Varambally, S., Dhanasekaran, S. M., Zhou, M., Barrette, T. R., Kumar-Sinha, C., Sanda, M. G., Ghosh, D., Pienta, K. J., Sewalt, R. G. A. B., Otte, A. P., et al. (2002) · Nature · doi:10.1038/nature01075 · Cited by 2,717
Tumour heterogeneity and cancer cell plasticity
Meacham, C. E., & Morrison, S. J. (2013) · Nature · doi:10.1038/nature12624 · Cited by 2,526
Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing
Ding, L., Ley, T. J., Larson, D. E., Miller, C. A., Koboldt, D. C., Welch, J. S., Ritchey, J. K., Young, M. A., Lamprecht, T., McLellan, M. D., et al. (2012) · Nature · doi:10.1038/nature10738 · Cited by 1,993

Show all 96 references

Sorted by citations

The Different Mechanisms of Cancer Drug Resistance: A Brief Review
Mansoori, B., Mohammadi, A., Davudian, S., Shirjang, S., & Baradaran, B. (2017) · Advanced Pharmaceutical Bulletin · doi:10.15171/apb.2017.041 · Cited by 1,957
The rediscovery of platinum-based cancer therapy
Rottenberg, S., Disler, C., & Perego, P. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-020-00308-y · Cited by 993
Targeting MAPK Signaling in Cancer: Mechanisms of Drug Resistance and Sensitivity
Lee, S., Rauch, J., & Kölch, W. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21031102 · Cited by 823
Tumorigenesis: it takes a village
Tabassum, D. P., & Polyák, K. (2015) · Nature reviews. Cancer · doi:10.1038/nrc3971 · Cited by 558
Apoptosis Deregulation and the Development of Cancer Multi-Drug Resistance
Neophytou, C. M., Trougakos, I. P., Erin, N., & Papageorgis, P. (2021) · Cancers · doi:10.3390/cancers13174363 · Cited by 392
Aldehyde Dehydrogenases: Not Just Markers, but Functional Regulators of Stem Cells
Vassalli, G. (2019) · Stem Cells International · doi:10.1155/2019/3904645 · Cited by 296
Targeting the CoREST complex with dual histone deacetylase and demethylase inhibitors
Kalin, J. H., Wu, M., Gómez, A. V., Song, Y., Das, J., Hayward, D., Adejola, N., Wu, M., Panova, I. P., Chung, H. J., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02242-4 · Cited by 239
Mechanisms of Resistance to Antibody–Drug Conjugates
Loganzo, F., Sung, M. S., & Gerber, H. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0408 · Cited by 237
Targeting CDK9 Reactivates Epigenetically Silenced Genes in Cancer
Zhang, H., Pandey, S., Travers, M. E., Sun, H., Morton, G. C., Madžo, J., Chung, W., Khowsathit, J., Pérez, Ó. C., Barrero, C. A., et al. (2018) · Cell · doi:10.1016/j.cell.2018.09.051 · Cited by 223
Preclinical and Clinical Development of Noncoding RNA Therapeutics for Cardiovascular Disease
Huang, C.-K., Kafert-Kasting, S., & Thum, T. (2020) · Circulation Research · doi:10.1161/circresaha.119.315856 · Cited by 217
Long non-coding RNAs regulate drug resistance in cancer
Liu, K., Gao, L., Ma, X., Huang, J., Chen, J., Zeng, L., Ashby, C. R., Zou, C., & Chen, Z. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01162-0 · Cited by 204
Multi-stage mechanisms of tumor metastasis and therapeutic strategies
Liu, Z., Chen, J., Ren, Y., Liu, S., Ba, Y., Zuo, A., Luo, P., Cheng, Q., Xu, H., & Han, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01955-5 · Cited by 218
The role of polyphenols in overcoming cancer drug resistance: a comprehensive review
Dana, P. M., Sadoughi, F., Asemi, Z., & Yousefi, B. (2022) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-021-00301-9 · Cited by 190
Principles and mechanisms of non-genetic resistance in cancer
Bell, C. C., & Gilan, O. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0648-6 · Cited by 190
Cancer drug resistance: redox resetting renders a way
Liu, Y., Li, Q., Zhou, L., Xie, N., Nice, E. C., Zhang, H., Huang, C., & Lei, Y. (2016) · Oncotarget · doi:10.18632/oncotarget.8600 · Cited by 182
Single-cell RNA sequencing reveals intrinsic and extrinsic regulatory heterogeneity in yeast responding to stress
Gasch, A. P., Yu, F. B., Hose, J., Escalante, L. E., Place, M., Bacher, R. L., Kanbar, J. N., Ciobanu, D., Sandor, L., Grigoriev, I. V., et al. (2017) · PLoS Biology · doi:10.1371/journal.pbio.2004050 · Cited by 162
Circular RNAs: characteristics, biogenesis, mechanisms and functions in liver cancer
Shen, H., Liu, B., Xu, J., Zhang, B., Wang, Y., Shi, L., & Cai, X. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01145-8 · Cited by 172
Synthesis, Evaluation, and Mechanism Study of Novel Indole-Chalcone Derivatives Exerting Effective Antitumor Activity Through Microtubule Destabilization in Vitro and in Vivo
Yan, J., Chen, J., Zhang, S., Hu, J., Huang, L., & Li, X. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00021 · Cited by 165
RNA therapy: Are we using the right molecules?
Yu, A., Jian, C., Yu, A. H., & Tu, M. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.11.011 · Cited by 167
Epigenetics of dementia: understanding the disease as a transformation rather than a state
Maloney, B., & Lahiri, D. K. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00065-x · Cited by 159
Chimeric HDAC inhibitors: Comprehensive review on the HDAC‐based strategies developed to combat cancer
Hesham, H. M., Lasheen, D. S., & Abouzid, K. A. M. (2018) · Medicinal Research Reviews · doi:10.1002/med.21505 · Cited by 149
Extracellular vesicles as a novel source of biomarkers in liquid biopsies for monitoring cancer progression and drug resistance
Vasconcelos, M. H., Caires, H. R., Ābols, A., Xavier, C. P. R., & Linē, A. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100647 · Cited by 150
Exploiting the Epigenome to Control Cancer-Promoting Gene-Expression Programs
Brien, G. L., Valerio, D. G., & Armstrong, S. A. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.03.007 · Cited by 155
BET Inhibitors Suppress ALDH Activity by Targeting ALDH1A1 Super-Enhancer in Ovarian Cancer
Yokoyama, Y., Zhu, H., Lee, J., Kossenkov, A. V., Wu, S. Y., Wickramasinghe, J. M., Yin, X., Palozola, K. C., Gardini, A., Showe, L. C., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0854 · Cited by 144
Mathematical modeling and computational prediction of cancer drug resistance
Sun, X., & Hu, B. X. (2017) · Briefings in Bioinformatics · doi:10.1093/bib/bbx065 · Cited by 142
Mathematical Modeling of Therapy-induced Cancer Drug Resistance: Connecting Cancer Mechanisms to Population Survival Rates
Sun, X., Bao, J., & Shao, Y. (2016) · Scientific Reports · doi:10.1038/srep22498 · Cited by 133
CellBox: Interpretable Machine Learning for Perturbation Biology with Application to the Design of Cancer Combination Therapy
Yuan, B., Shen, C., Luna, A., Korkut, A., Marks, D. S., Ingraham, J., & Sander, C. (2020) · Cell Systems · doi:10.1016/j.cels.2020.11.013 · Cited by 125
Fibrin Stiffness Mediates Dormancy of Tumor-Repopulating Cells via a Cdc42-Driven Tet2 Epigenetic Program
Liu, Y., Lv, J., Liang, X., Yin, X., Zhang, L., Chen, D., Jin, X., Fiskesund, R., Tang, K., Ma, J., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3719 · Cited by 123
Characterization of acquired paclitaxel resistance of breast cancer cells and involvement of ABC transporters
Němcová‐Fürstová, V., Kopperová, D., Balušíková, K., Ehrlichová, M., Brynychová, V., Václavíková, R., Daniel, P., Souček, P., & Kovár̆, J. (2016) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2016.09.020 · Cited by 120
Blueprint for cancer research: Critical gaps and opportunities
Elmore, L. W., Greer, S. F., Daniels, E. C., Saxe, C. C., Melner, M. H., Krawiec, G. M., Cance, W. G., & Phelps, W. C. (2020) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21652 · Cited by 124
Intron retention is regulated by altered MeCP2-mediated splicing factor recruitment
Wong, J. J. L., Gao, D., Nguyen, T. V., Kwok, C., van Geldermalsen, M., Middleton, R., Pinello, N., Thoeng, A., Nagarajah, R., Holst, J., et al. (2017) · Nature Communications · doi:10.1038/ncomms15134 · Cited by 110
Two-in-One Chemogene Assembled from Drug-Integrated Antisense Oligonucleotides To Reverse Chemoresistance
Mou, Q., Ma, Y., Ding, F., Gao, X., Yan, D., Zhu, X., & Zhang, C. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.8b13875 · Cited by 109
Cell population heterogeneity and evolution towards drug resistance in cancer: Biological and mathematical assessment, theoretical treatment optimisation
Chisholm, R. H., Lorenzi, T., & Clairambault, J. (2016) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2016.06.009 · Cited by 99
Targeting epigenetic regulatory machinery to overcome cancer therapy resistance
Guo, L., Lee, Y., Zhou, Y., & Huang, Y. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.12.022 · Cited by 101
Targeting HDAC with a novel inhibitor effectively reverses paclitaxel resistance in non-small cell lung cancer via multiple mechanisms
wang, L., Li, H., Ren, Y., Zou, S., Fang, W., Jiang, X., Li, J., Li, M., Liu, X., Yuan, X., et al. (2016) · Cell Death and Disease · doi:10.1038/cddis.2015.328 · Cited by 93
Multiplexed, single-molecule, epigenetic analysis of plasma-isolated nucleosomes for cancer diagnostics
Fedyuk, V., Erez, N., Furth, N., Beresh, O., Andreishcheva, E. N., Shinde, A., Jones, D. R., Zakai, B. B., Mavor, Y., Peretz, T., et al. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01447-3 · Cited by 94
Micrornas as Pharmacogenomic Biomarkers for Drug Efficacy and Drug Safety Assessment
Koturbash, I., Tolleson, W. H., Guo, L., Yu, D., Chen, S., Hong, H., Mattes, W. B., & Ning, B. (2015) · Biomarkers in Medicine · doi:10.2217/bmm.15.89 · Cited by 90
Dual EZH2 and EHMT2 histone methyltransferase inhibition increases biological efficacy in breast cancer cells
Curry, E. W., Green, I., Chapman‐Rothe, N., Shamsaei, E., Kandil, S., Cherblanc, F., Payne, L., Bell, E., Ganesh, T., Srimongkolpithak, N., et al. (2015) · Clinical Epigenetics · doi:10.1186/s13148-015-0118-9 · Cited by 91
Self-citation
Epigenome-wide DNA methylation analysis of small cell lung cancer cell lines suggests potential chemotherapy targets
Krushkal, J., Silvers, T. R., Reinhold, W. C., Sonkin, D., Vural, S., Connelly, J., Varma, S., Meltzer, P. S., Kunkel, M. W., Rapisarda, A., et al. (2020) · Clinical Epigenetics · doi:10.1186/s13148-020-00876-8 · Cited by 84
Super-enhancers: a new frontier for epigenetic modifiers in cancer chemoresistance
Li, G., Qu, Q., Qi, T.-T., Teng, X.-Q., Zhu, H., Wang, J., Lu, Q., & Qu, J. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01974-y · Cited by 89
Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes
Venkadakrishnan, V. B., Presser, A. G., Singh, R., Booker, M. A., Traphagen, N. A., Weng, K., Voss, N. C. E., Mahadevan, N. R., Mizuno, K., Puca, L., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51156-5 · Cited by 84
The evolutionary theory of cancer: challenges and potential solutions
Laplane, L., & Maley, C. C. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00734-2 · Cited by 89
Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: Different models for different questions
Alkema, N. G., Wisman, G. B. A., van der Zee, A. G. J., van Vugt, M. A. T. M., & de Jong, S. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.11.005 · Cited by 84
Epidrug Repurposing: Discovering New Faces of Old Acquaintances in Cancer Therapy
Montalvo-Casimiro, M., González‐Barrios, R., Meraz-Rodríguez, M. A., Juárez-González, V. T., Arriaga-Canon, C., & Herrera, L. A. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.605386 · Cited by 82
Asymptotic analysis and optimal control of an integro-differential system modelling healthy and cancer cells exposed to chemotherapy
Pouchol, C., Clairambault, J., Lorz, A., & Trélat, E. (2017) · Journal de Mathématiques Pures et Appliquées · doi:10.1016/j.matpur.2017.10.007 · Cited by 75
EZH2 Modifies Sunitinib Resistance in Renal Cell Carcinoma by Kinome Reprogramming
Adelaiye-Ogala, R. M., Budka, J. A., Damayanti, N. P., Arrington, J. V., Ferris, M. W., Hsu, C.-C., Chintala, S., Orillion, A. R., Miles, K. M., Shen, L., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0899 · Cited by 78
WP1130 increases doxorubicin sensitivity in hepatocellular carcinoma cells through usp9x-dependent p53 degradation
Liu, H., Chen, W., Liang, C., Chen, B. W., Zhi, X., Zhang, S., Zheng, X., Bai, X., & Liang, T. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.03.001 · Cited by 74
Broad antifungal resistance mediated by RNAi-dependent epimutation in the basal human fungal pathogen Mucor circinelloides
Chang, Z., Billmyre, R. B., Lee, S. C., & Heitman, J. (2019) · PLOS Genetics · doi:10.1371/journal.pgen.1007957 · Cited by 72
Isorhamnetin suppresses PANC-1 pancreatic cancer cell proliferation through S phase arrest
Wang, J., Quan, Q., Ji, R., Guo, X., Zhang, J., Li, X., & Liu, Y. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.09.105 · Cited by 72
Dual responsive micelles capable of modulating miRNA-34a to combat taxane resistance in prostate cancer
Lin, F., Wen, D., Wang, X., & Mahato, R. I. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.10.036 · Cited by 72
Ovarian cancer stem cells: What progress have we made?
Al-Alem, L., Pandya, U. M., Baker, A. T., Bellio, C., Zarrella, B., Clark, J., DiGloria, C. M., & Rueda, B. R. (2018) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2018.12.010 · Cited by 71
MicroRNAs are important regulators of drug resistance in colorectal cancer
Zhang, Y., & Wang, J. (2017) · Biological Chemistry · doi:10.1515/hsz-2016-0308 · Cited by 68
Combination of cancer-specific prodrug nanoparticle with Bcl-2 inhibitor to overcome acquired drug resistance
Kim, J., Shim, M. K., Yang, S., Moon, Y., Song, S., Choi, J., Kim, J., & Kim, K. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.10.065 · Cited by 70
PRMT1 is a novel molecular therapeutic target for clear cell renal cell carcinoma
Wang, J., Wang, C., Xu, P., Li, X., Lu, Y., Jin, D., Yin, X., Jiang, H., Huang, J. L., Xiong, H., et al. (2021) · Theranostics · doi:10.7150/thno.42345 · Cited by 70
EZH2-DNMT1-mediated epigenetic silencing of miR-142-3p promotes metastasis through targeting ZEB2 in nasopharyngeal carcinoma
Li, Y., He, Q., Wen, X., Hong, X.-H., Yang, X., Tang, X.-R., Zhang, P., Lei, Y., Sun, Y. H., Zhang, J., et al. (2018) · Cell Death and Differentiation · doi:10.1038/s41418-018-0208-2 · Cited by 70
Lessons from the Crypt: HMGA1—Amping up Wnt for Stem Cells and Tumor Progression
Resar, L. M. S., Chia, L., & Xian, L. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3045 · Cited by 69
Fibronectin‐1 modulated by the long noncoding RNA OIP5‐AS1/miR‐200b‐3p axis contributes to doxorubicin resistance of osteosarcoma cells
Zhu, K., Zhang, C., Xiao‐Long, M., & Zhang, L. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27435 · Cited by 69
Probing the interaction between the histone methyltransferase/deacetylase subunit RBBP4/7 and the transcription factor BCL11A in epigenetic complexes
Moody, R., Lo, M., Meagher, J. L., Lin, C.-C. A., Stevers, N. O., Tinsley, S. L., Jung, I., Matvekas, A., Stuckey, J. A., & Sun, D. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.811463 · Cited by 70
Harnessing Tumor Evolution to Circumvent Resistance
McNamara, K. L., & Curtis, C. N. (2018) · Trends in Genetics · doi:10.1016/j.tig.2018.05.007 · Cited by 70
Determinants of nutrient limitation in cancer
Sullivan, M. R., & Heiden, M. G. V. (2019) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409238.2019.1611733 · Cited by 70
Changes of O6-Methylguanine DNA Methyltransferase (MGMT) Promoter Methylation in Glioblastoma Relapse—A Meta-Analysis Type Literature Review
Feldheim, J., Kessler, A. F., Monoranu, C. M., Ernestus, R., Löhr, M., & Hagemann, C. (2019) · Cancers · doi:10.3390/cancers11121837 · Cited by 67
DREAMing: a simple and ultrasensitive method for assessing intratumor epigenetic heterogeneity directly from liquid biopsies
Pisanic, T. R., Athamanolap, P., Poh, W., Chen, C., Hulbert, A., Brock, M. V., Herman, J. G., & Wang, T. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv795 · Cited by 67
Circulating tumor cell profiling for precision oncology
Labib, M., & Kelley, S. O. (2021) · Molecular Oncology · doi:10.1002/1878-0261.12901 · Cited by 68
Epigenetic mechanisms and therapeutic targets of chemotherapy resistance in epithelial ovarian cancer
Borley, J., & Brown, R. E. (2015) · Annals of Medicine · doi:10.3109/07853890.2015.1043140 · Cited by 67
Self-citation
Astragaloside IV Enhances Cisplatin Chemosensitivity in Non-Small Cell Lung Cancer Cells Through Inhibition of B7-H3
He, C.-S., Liu, Y.-C., Xu, Z., Dai, P.-C., Chen, X., & Jin, D.-H. (2016) · Cellular Physiology and Biochemistry · doi:10.1159/000453175 · Cited by 65
Understanding the role of phenotypic switching in cancer drug resistance
Gunnarsson, E. B., De, S., Leder, K., & Foo, J. (2020) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2020.110162 · Cited by 68
Biological implications and therapeutic significance of DNA methylation regulated genes in cervical cancer
Bhat, S., Kabekkodu, S. P., Noronha, A., & Satyamoorthy, K. (2015) · Biochimie · doi:10.1016/j.biochi.2015.12.018 · Cited by 68
Epigenetic Regulation of the Homeobox Gene MSX1 Associates with Platinum-Resistant Disease in High-Grade Serous Epithelial Ovarian Cancer
Bonito, N. A., Borley, J., Wilhelm-Benartzi, C. S., Ghaem‐Maghami, S., & Brown, R. E. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1669 · Cited by 64
Self-citation
Oxygen nanobubbles revert hypoxia by methylation programming
Bhandari, P. N., Cui, Y., Elzey, B. D., Goergen, C. J., Long, C. M., & Irudayaraj, J. (2017) · Scientific Reports · doi:10.1038/s41598-017-08988-7 · Cited by 64
Pharmacoepigenetics and Toxicoepigenetics: Novel Mechanistic Insights and Therapeutic Opportunities
Lauschke, V. M., Barragán, I., & Ingelman‐Sundberg, M. (2017) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010617-053021 · Cited by 63
Overcoming Resistance to Drugs Targeting KRAS Mutation
Jiao, D., & Yang, S. (2020) · The Innovation · doi:10.1016/j.xinn.2020.100035 · Cited by 61
Modeling of signaling crosstalk-mediated drug resistance and its implications on drug combination
Sun, X., Bao, J., You, Z., Chen, X., & Cui, J. (2016) · Oncotarget · doi:10.18632/oncotarget.11745 · Cited by 59
Computational Methods for the Analysis and Prediction of EGFR-Mutated Lung Cancer Drug Resistance: Recent Advances in Drug Design, Challenges and Future Prospects
Qureshi, R., Zou, B., Alam, T., Wu, J., Lee, V. H.-F., & Yan, H. (2022) · IEEE Transactions on Computational Biology and Bioinformatics · doi:10.1109/tcbb.2022.3141697 · Cited by 61
Protein degradation: expanding the toolbox to restrain cancer drug resistance
Ming, H., Li, B., Jiang, J., Qin, S., Nice, E. C., He, W., Lang, T., & Huang, C. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01398-5 · Cited by 64
Multicellular gene network analysis identifies a macrophage-related gene signature predictive of therapeutic response and prognosis of gliomas
Sun, X., Liu, X., Xia, M., Shao, Y., & Zhang, X. D. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-1908-1 · Cited by 58
Eukaryotic translation initiation factor 5A2 (eIF5A2) regulates chemoresistance in colorectal cancer through epithelial mesenchymal transition
Bao, Y., Lu, Y., Wang, X., Feng, W., Sun, X., Guo, H., Tang, C., Zhang, X., Shi, Q., & Yu, H. (2015) · Cancer Cell International · doi:10.1186/s12935-015-0250-9 · Cited by 56
Glycosylation in Cancer: Interplay between Multidrug Resistance and Epithelial-to-Mesenchymal Transition?
da Fonseca, L. M., da Silva, V. A., Freire‐de‐Lima, L., Previato, J. O., Mendonça‐Previato, L., & Capella, M. A. M. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00158 · Cited by 56
pH-Sensitive Nano-Complexes Overcome Drug Resistance and Inhibit Metastasis of Breast Cancer by Silencing Akt Expression
Yin, J., Lang, T., Cun, D., Zheng, Z., Huang, Y. L., Yin, Q., Yu, H., & Li, Y. (2017) · Theranostics · doi:10.7150/thno.21516 · Cited by 56
A five-DNA methylation signature act as a novel prognostic biomarker in patients with ovarian serous cystadenocarcinoma
Guo, W., Zhu, L., Yu, M., Zhu, R., Chen, Q., & Wang, Q. (2018) · Clinical Epigenetics · doi:10.1186/s13148-018-0574-0 · Cited by 54
Pan-cancer analysis of frequent DNA co-methylation patterns reveals consistent epigenetic landscape changes in multiple cancers
Zhang, J., & Huang, K. (2017) · BMC Genomics · doi:10.1186/s12864-016-3259-0 · Cited by 55
Small-Molecule Inhibitors Overcome Epigenetic Reprogramming for Cancer Therapy
Xiao, W., Zhou, Q., Wen, X., Wang, R., Liu, R., Wang, T., Shi, J., Hu, Y., & Hou, J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.702360 · Cited by 51
Epigenetic effects of RRx-001: a possible unifying mechanism of anticancer activity
Zhao, H., Ning, S., Scicinski, J. J., Oronsky, B. T., Knox, S. J., & Peehl, D. M. (2015) · Oncotarget · doi:10.18632/oncotarget.6526 · Cited by 53
Induction of DNMT3B by PGE2 and IL6 at Distant Metastatic Sites Promotes Epigenetic Modification and Breast Cancer Colonization
So, J. Y., Skrypek, N., Yang, H. H., Merchant, A. S., Nelson, G. W., Chen, W.-D. D., Ishii, H., Chen, J. M., Hu, G., Achyut, B. R., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3339 · Cited by 53
Genes Predisposed to DNA Hypermethylation during Acquired Resistance to Chemotherapy Are Identified in Ovarian Tumors by Bivalent Chromatin Domains at Initial Diagnosis
Curry, E. W., Zeller, C., Masrour, N., Patten, D. K., Gallon, J., Wilhelm-Benartzi, C. S., Ghaem‐Maghami, S., Bowtell, D. D. L., & Brown, R. E. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-1650 · Cited by 54
Self-citation
The Impact of Epigenetic Modifications on Adaptive Resistance Evolution in Glioblastoma
Wu, Q., Berglund, A., & Etame, A. B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158324 · Cited by 54
H3-K27M-mutant nucleosomes interact with MLL1 to shape the glioma epigenetic landscape
Furth, N., Algranati, D., Dassa, B., Beresh, O., Fedyuk, V., Morris, N., Kasper, L. H., Jones, D. R., Monje, M., Baker, S. J., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110836 · Cited by 52
Integrated single-cell and bulk gene expression and ATAC-seq reveals heterogeneity and early changes in pathways associated with resistance to cetuximab in HNSCC-sensitive cell lines
Kagohara, L. T., Zamunér, F. T., Davis-Marcisak, E. F., Sharma, G., Considine, M., Allen, J., Yegnasubramanian, S., Gaykalova, D. A., & Fertig, E. J. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0851-5 · Cited by 50
Intratumor Heterogeneity: Novel Approaches for Resolving Genomic Architecture and Clonal Evolution
Gupta, R. G., & Somer, R. A. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0070 · Cited by 49
Epigenome Remodeling in Cholangiocarcinoma
O’Rourke, C. J., Lafuente-Barquero, J. F., & Andersen, J. B. (2019) · Trends in cancer · doi:10.1016/j.trecan.2019.05.002 · Cited by 48
Chromatin accessibility analysis reveals that TFAP2A promotes angiogenesis in acquired resistance to anlotinib in lung cancer cells
Zhang, L., Lü, J., Liu, R., Hu, M., Zhao, Y., Tan, S. H., Wang, S.-Y., Zhang, B., Nie, W., Dong, Y., et al. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-0421-7 · Cited by 48
Slow-growing cells within isogenic populations have increased RNA polymerase error rates and DNA damage
van Dijk, D., Dhar, R., Missarova, A., Espinar, L., Blevins, W. R., Lehner, B., & Carey, L. B. (2015) · Nature Communications · doi:10.1038/ncomms8972 · Cited by 43
Combination therapy with protein kinase inhibitor H89 and Tetrandrine elicits enhanced synergistic antitumor efficacy
Yu, M., Liu, T., Chen, Y.-C., Li, Y., & Li, W. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0779-2 · Cited by 51
Epigenetic reprogramming and potential application of epigenetic-modifying drugs in acquired chemotherapeutic resistance
Ponnusamy, L., Mahalingaiah, P. K. S., & Singh, K. P. (2019) · Advances in clinical chemistry · doi:10.1016/bs.acc.2019.07.011 · Cited by 48
Glioblastoma Recurrence and the Role of O6-Methylguanine–DNA Methyltransferase Promoter Methylation
Storey, K. M., Leder, K., Hawkins-Daarud, A. J., Swanson, K. R., Ahmed, A. U., Rockne, R. C., & Foo, J. (2019) · JCO Clinical Cancer Informatics · doi:10.1200/cci.18.00062 · Cited by 50
Epigenetic Modulation with Histone Deacetylase Inhibitors in Combination with Immunotherapy
Park, J., Thomas, S., & Münster, P. N. (2015) · Epigenomics · doi:10.2217/epi.15.16 · Cited by 47
Evolution of cancer cell populations under cytotoxic therapy and treatment optimisation: insight from a phenotype-structured model
de Almeida, L. N., Bagnerini, P., Fabrini, G., Hughes, B. D., & Lorenzi, T. (2019) · ESAIM Mathematical Modelling and Numerical Analysis · doi:10.1051/m2an/2019010 · Cited by 44
Dual inhibitors of HDAC and other epigenetic regulators: A novel strategy for cancer treatment
Shirbhate, E., Singh, V. P., Jahoriya, V., Mishra, A., Veerasamy, R., Tiwari, A. K., & Rajak, H. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115938 · Cited by 47
Epigenetic drugs and their molecular targets in testicular germ cell tumours
Jostes, S., Nettersheim, D., & Schorle, H. (2019) · Nature Reviews Urology · doi:10.1038/s41585-019-0154-x · Cited by 45
Inhibition of EZH2 Attenuates Sorafenib Resistance by Targeting NOTCH1 Activation-Dependent Liver Cancer Stem Cells via NOTCH1-Related MicroRNAs in Hepatocellular Carcinoma
Wang, S., Cai, L., Zhang, F., Shang, X., Xiao, R., & Zhou, H. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.01.002 · Cited by 45
EZH1/2 inhibition augments the anti-tumor effects of sorafenib in hepatocellular carcinoma
Kusakabe, Y., Chiba, T., Oshima, M., Koide, S., Rizq, O., Aoyama, K., Ao, J., Kaneko, T., Kanzaki, H., Kanayama, K., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-00889-0 · Cited by 45

Authors: Brown, R., Curry, E., Magnani, L., Wilhelm-Benartzi, C. S., & Borley, J.
Affiliations: Hammersmith Hospital (GB)
Corresponding author: Brown, Robert
ORCID: Brown, Robert
Curry, Edward
Magnani, Luca
Wilhelm-Benartzi, Charlotte S.
Venue: Nature Reviews Cancer
Publisher: Springer Science and Business Media LLC
Published: 2014-09-25
Volume: 14
Issue: 11
Pages: 747-753
ISSN: 1474-175X (ISSN-L)
1474-1768
DOI: 10.1038/nrc3819
OpenAlex: W2095124748
Cited by: 301
References: 96
Citations by year: 2026: 4 · 2025: 16 · 2024: 23 · 2023: 21 · 2022: 26 · 2021: 41 · 2020: 37 · 2019: 34 · 2018: 27 · 2017: 23 · 2016: 30 · 2015: 18 · 2014: 1
FWCI: 2.29
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature reviews. Cancer (publishedVersion)
PubMed (publishedVersion)
ORCA Online Research @Cardiff (Cardiff University) (submittedVersion)
Funders: Cancer Research UK (13086, A13086, 15954)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
Keywords: epigenetic heterogeneity, acquired drug resistance, cancer, epigenetic targeting, chemoresistance, gene expression evolution
MeSH terms: Animals, Humans, Neoplasms, Gene Expression Regulation, Neoplastic, Drug Resistance, Neoplasm, Epigenesis, Genetic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Poised epigenetic states and acquired drug resistance in cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks